SCHEMBL207360

SCHEMBL207360

CCCCCCCCOc1ccc(Nc2nc(-c3ccc(O)c(C(N)=O)c3)cs2)cc1C(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 2/20 0.49
WDR77 Q9BQA1 2/20 0.49
S1PR1 P21453 4/20 0.48
CFTR P13569 1/20 0.48
MAPT P10636 2/20 0.47
GAA P10253 1/20 0.47
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
EPHA2 P29317 1/20 0.44
KDR P35968 1/20 0.44
EPHB4 P54760 1/20 0.44
HPGDS O60760 1/20 0.43
HSPD1 P10809 1/20 0.41
HSPE1 P61604 1/20 0.41
CSNK2A2 P19784 1/20 0.41
CSNK2B P67870 1/20 0.41
CSNK2A1 P68400 1/20 0.41
CSNK2A3 Q8NEV1 1/20 0.41
SIRT5 Q9NXA8 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206218 0.99 PRMT5 (0.50) PRMT5WDR77S1PR1CFTRMAPT
SCHEMBL207803 0.90 HSPD1 (0.50) PRMT5WDR77S1PR1CFTRMAPT
SCHEMBL250488 0.89 HSPD1 (0.51) PRMT5WDR77S1PR1CFTRMAPT
SCHEMBL205627 0.87 PRMT5 (0.51) PRMT5WDR77CFTRMAPTGAA
SCHEMBL204874 0.86 S1PR1 (0.47) PRMT5WDR77S1PR1CFTRMAPT
SCHEMBL206476 0.85 S1PR1 (0.46) PRMT5WDR77S1PR1CFTRMAPT
SCHEMBL208017 0.85 MAPT (0.48) PRMT5WDR77CFTRMAPTGAA
SCHEMBL2697859 0.85 ALOX5 (0.54) PRMT5WDR77MAPTGAAMEN1
SCHEMBL250505 0.85 ALOX5 (0.54) PRMT5WDR77MAPTGAAMEN1
SCHEMBL206434 0.85 CFTR (0.49) PRMT5WDR77CFTRMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US claimed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 PRMT5 1987/4885WDR77 2054/4885S1PR1 1259/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 PRMT5 1987/4885WDR77 2054/4885S1PR1 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.